Search for: All records

Over the last three decades, cold atmospheric plasma (CAP) has been heavily investigated in a wide range of biological applications, including wound healing, microorganism sterilization, and cancer treatment. Atmospheric pressure plasma jets (APPJs) are the most common plasma sources in plasma medicine. An APPJ’s size determines its application range and approach in treatment. In this study, we demonstrated the real-time recognition of an APPJ’s plasma plume output using computer vision (CV), dramatically improving the measurement speed compared to the traditional method of using the naked eye. Our work provides a framework to monitor an aspect of an APPJ’s performance in real time, which is a necessary step to achieving an intelligent CAP source. 

CAP is an ionized gas generated under atmospheric pressure conditions. Due to its reactive chemical components and near-room temperature nature, CAP has promising applications in diverse branches of medicine, including microorganism sterilization, biofilm inactivation, wound healing, and cancer therapy. Currently, hundreds of in vitro demonstrations of CAP-based cancer treatments have been reported. However, preclinical studies, particularly in vivo studies, are pivotal to achieving a final clinical application. Here, we comprehensively introduced the research status of the preclinical usage of CAP in cancer treatment, by primarily focusing on the in vivo studies over the past decade. We summarized the primary research strategies in preclinical and clinical studies, including transdermal CAP treatment, post-surgical CAP treatment, CAP-activated solutions treatment, and sensitization treatment to drugs. Finally, the underlying mechanism was discussed based on the latest understanding.